BRPI0919898A2 - 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3 - Google Patents

4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3

Info

Publication number
BRPI0919898A2
BRPI0919898A2 BRPI0919898A BRPI0919898A BRPI0919898A2 BR PI0919898 A2 BRPI0919898 A2 BR PI0919898A2 BR PI0919898 A BRPI0919898 A BR PI0919898A BR PI0919898 A BRPI0919898 A BR PI0919898A BR PI0919898 A2 BRPI0919898 A2 BR PI0919898A2
Authority
BR
Brazil
Prior art keywords
tetrahydrothienopyridines
kcnq2
modulators
substituted
Prior art date
Application number
BRPI0919898A
Other languages
English (en)
Inventor
Achim Kless
Beatrix Merla
Gregor Bahrenberg
Klaus Schiene
Sven Kühnert
Wolfgang Schröder
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BRPI0919898A2 publication Critical patent/BRPI0919898A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0919898A 2008-10-24 2009-10-22 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3 BRPI0919898A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08018617 2008-10-24
PCT/EP2009/007567 WO2010046108A1 (de) 2008-10-24 2009-10-22 Substituierte 4,5,6,7-tetrahydrothienopyridine als kcnq2/3 modulatoren zur behandlung von schmerz, epilepsie und harninkontinenz

Publications (1)

Publication Number Publication Date
BRPI0919898A2 true BRPI0919898A2 (pt) 2016-02-16

Family

ID=40383750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919898A BRPI0919898A2 (pt) 2008-10-24 2009-10-22 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3

Country Status (15)

Country Link
US (1) US20100105722A1 (pt)
EP (1) EP2350093B1 (pt)
JP (1) JP2012506395A (pt)
AU (1) AU2009306722A1 (pt)
BR (1) BRPI0919898A2 (pt)
CA (1) CA2739740A1 (pt)
CY (1) CY1113373T1 (pt)
DK (1) DK2350093T3 (pt)
ES (1) ES2392758T3 (pt)
HR (1) HRP20120822T1 (pt)
MX (1) MX2011003849A (pt)
PL (1) PL2350093T3 (pt)
PT (1) PT2350093E (pt)
SI (1) SI2350093T1 (pt)
WO (1) WO2010046108A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI565465B (zh) * 2010-08-27 2017-01-11 歌林達股份有限公司 作為ｋｃｎｑ２／３調節劑之被取代之喹啉－３－甲醯胺
KR20130100300A (ko) * 2010-08-27 2013-09-10 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ２-옥시-퀴놀린-３-카복스아미드
BR112013004690A2 (pt) 2010-08-27 2016-05-10 Gruenenthal Gmbh 2-oxo-e 2-tioxo-di-hidroquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
TW201211007A (en) 2010-08-27 2012-03-16 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
AU2011297937B2 (en) 2010-09-01 2015-10-01 Grunenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
US8552200B2 (en) 2010-10-20 2013-10-08 Gruenenthal Gmbh Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
US9168259B2 (en) 2010-10-20 2015-10-27 Grünenthal GmbH Substituted 6-amino-nicotinamides as KCNQ2/3 modulators
AU2013235487B2 (en) 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
MX2014012491A (es) 2012-04-18 2014-11-14 Grünenthal GmbH 4-aminobenzamidas sustituidas como moduladores de kcnq2/3.
BR112014025840A2 (pt) 2012-04-18 2017-07-18 Gruenenthal Gmbh 6-amino-nicotinamidas substituídas tendo um grupo contendo oh como moduladores de kcnq2/3.
EP2925759A1 (en) 2012-11-28 2015-10-07 Grünenthal GmbH Heteroquinoline-3-carboxamides as kcnq2/3 modulators
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
US9284286B2 (en) 2012-11-28 2016-03-15 Grünenthal GmbH Specific carboxamides as KCNQ2/3 modulators
EP4135698A4 (en) * 2020-04-17 2024-08-14 The Trustees of Indiana University SMALL MOLECULE ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS
US11931356B1 (en) 2022-11-30 2024-03-19 The Trustees Of Indiana University Compositions and methods for treating human papilloma virus infections
EP4727553A2 (en) 2023-06-13 2026-04-22 The Trustees of Indiana University Small molecule antiviral drug treatment for human papillomavirus infections
WO2025153715A1 (en) * 2024-01-19 2025-07-24 Scenic Biotech Bv Heterocyclic pla2g15 inhibitors and their use in therapy, in the treatment of diseases characterized by lysosomal dysregulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733750B1 (fr) * 1995-05-03 1997-06-13 Synthelabo Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
MXPA03007397A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
PL1753512T3 (pl) * 2004-05-28 2009-03-31 4Sc Ag Tetrahydropirydotiofeny
WO2005120642A2 (en) * 2004-06-11 2005-12-22 Altana Pharma Ag Tetrahydropyridothiophenes for treating hyperproliferative disorders
DE102006049452A1 (de) * 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
WO2009001128A1 (en) * 2007-06-26 2008-12-31 Astrazeneca Ab 1,2-cycl0hexane dicarboxamides as cathepsin inhibitors

Also Published As

Publication number Publication date
SI2350093T1 (sl) 2012-11-30
DK2350093T3 (da) 2012-11-12
AU2009306722A1 (en) 2010-04-29
MX2011003849A (es) 2011-05-23
CA2739740A1 (en) 2010-04-29
EP2350093B1 (de) 2012-10-03
HRP20120822T1 (hr) 2012-11-30
WO2010046108A1 (de) 2010-04-29
US20100105722A1 (en) 2010-04-29
CY1113373T1 (el) 2016-06-22
PL2350093T3 (pl) 2013-01-31
EP2350093A1 (de) 2011-08-03
ES2392758T3 (es) 2012-12-13
JP2012506395A (ja) 2012-03-15
PT2350093E (pt) 2012-11-02

Similar Documents

Publication Publication Date Title
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
BRPI1008948A2 (pt) nicotinamida substituída como moduladores kcnq2/3.
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0914340A2 (pt) faixa de cabeça com coxim pivotal
CU24152B1 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BRPI0919295A2 (pt) 1h-benzimidazol-5-carboxamidas como agentes anti-inflamatórios.
BRPI0921327A2 (pt) Combinação de herbicida-protetor
BRPI0917980A2 (pt) subcanalização com aumento de potência
HRP20151058T1 (xx) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
BRPI0910229A2 (pt) Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos
EP2344471A4 (en) 7-PIPERIDINALKYL-3,4-dihydroquinolone DERIVATIVE
BR112013010957A2 (pt) 6-amino-nicotinamidas substituídas como moduladores kcnq2/3
UY33125A (es) Diaza-espiro-[5,5]-undecanos
BRPI1009428A2 (pt) 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
EP2321062A4 (en) Sprayer
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
BRPI0907108A2 (pt) escova de dentes.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
EP2259958A4 (en) LINKAGE
EP2459573A4 (en) SUBSTITUTED 1,2-AZABORIN HETEROCYCLES
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI0822525A2 (pt) gerar mapas de sites
BRPI1009519A2 (pt) 3-amino-2-mercaptoquinolina substituída como modulador de kcnq2/3.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.